Belgium’s mid-sized pharmaceutical company, UCB Group, has highlighted new understanding of the importance of axial spondyloarthritis and psoriatic arthritis, both of which are now believed to be more common than rheumatoid arthritis, as a factor in the development of its late-stage investigational selective IL-17A and IL-17F inhibitor, bimekizumab.
CEO Jean-Christophe Tellier reported that Phase III results involving bimekizumab are expected in the fourth quarter of this year, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?